Funder: National Institutes of Health

Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision)

Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.

Summary: Supports research on the mechanisms by which incretin mimetics (GLP-1, GIP-1, or dual agonists) impact cancer risk, with clinical trial option.

Key Information: Non-domestic (non-U.S.) entities are eligible; animal or human studies must include mechanistic endpoints, not just epidemiology.